Reinnervation of the rat musculocutaneous nerve stump after its direct reconnection with the C5 spinal cord segment by the nerve graft following avulsion of the ventral spinal roots: a comparison of intrathecal administration of brain-derived neurotrophic factor and Cerebrolysin.
Experimental model based on the C5 ventral root avulsion was used to evaluate the efficacy of brain-derived neurotrophic factor (BDNF) and Cerebrolysin treatment on motor neuron maintenance and survival resulted in the functional reinnervation of the nerve stump. In contrast to vehicle, BDNF treatment reduced the loss and atrophy of motor neurons and enhanced the regrowth axon sprouts into the distal stump of musculocutaneous nerve. However, the axon diameter of the myelinated fibers was smaller than those of control rats. The morphometric results were related to a low score in behavioral test similar to vehicle-treated rats. Cerebrolysin treatment greatly protected the motor neurons against cell death. Moreover, morphometric features of myelinated axons were better than those of rats treated with vehicle or BDNF. The mean score of grooming test suggested better results of the functional motor reinnervation than after BDNF administration. The majority of rescued motor neurons regenerating their axons through nerve graft in both BDNF- and Cerebrolysin-treated rats expressed choline acetyltransferase immunostaining. The results demonstrate that BDNF has more modest effects in preventing the death of motor neurons and functional recovery of injured motor nerve after root avulsion than Cerebrolysin.
Haninec
P
P
Department of Neurosurgery, 3rd Faculty of Medicine, Charles University, Prague, Czech Republic.
Dubový
P
P
Sámal
F
F
Houstava
L
L
Stejskal
L
L
D000596:Amino Acids / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D001369:Axons / Q000502:physiology; D001522:Behavior, Animal / Q000187:drug effects; D019208:Brain-Derived Neurotrophic Factor / Q000008:administration & dosage / Q000494:pharmacology*; D002795:Choline O-Acetyltransferase / Q000378:metabolism; D003911:Dextrans; D005260:Female; D005456:Fluorescent Dyes; D007150:Immunohistochemistry; D007278:Injections, Spinal; D009046:Motor Neurons / Q000187:drug effects / Q000502:physiology; D018482:Muscle, Skeletal / Q000294:innervation*; D009138:Musculocutaneous Nerve / Q000166:cytology / Q000502:physiology; D009413:Nerve Fibers, Myelinated / Q000502:physiology; D009416:Nerve Regeneration / Q000502:physiology*; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D012235:Rhodamines; D012867:Skin / Q000294:innervation*; D013116:Spinal Cord / Q000502:physiology*; D013126:Spinal Nerve Roots / Q000502:physiology*; D013127:Spinal Nerves / Q000502:physiology* / Q000637:transplantation*
D000596:Amino Acids; D019208:Brain-Derived Neurotrophic Factor; D003911:Dextrans; D005456:Fluorescent Dyes; C067661:Fluoro-Ruby; D018696:Neuroprotective Agents; D012235:Rhodamines; C006952:cerebrolysin; D002795:Choline O-Acetyltransferase